Information for Investors
UK & EU Investors
UK and EU investors should access further information via CrowdCube, the UK’s regulated equity crowdfunding platform.
US, Canada, Japan & China Investors
And other jurisdictions unable to invest through CrowdCube
Please contact Attomarker directly on:
info@attomarker.com
Risk Warning: Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.
About Attomarker
UK spin-out from the University of Exeter developing multiplex immunology diagnostics for infectious and post-viral conditions including Long COVID and Lyme. Proprietary, patented gold nanoparticle biophotonic sensors enable rapid, multi-biomarker analysis from a very small blood sample within 10 minutes.
Key Information
Investment type:
Equity
Pre-money valuation:
Share price:
Highlights
The Idea
Problem
Long COVID affects 65m people globally, with patients experiencing persistent, debilitating symptoms and poor diagnostic clarity. Lyme disease has challenges. Clinicians have few diagnostic options.
Solution
Attomarker COVID Antibody Spectrum Test measures antibody quantity and quality across several SARS-CoV-2 variants allowing endotype classification and care personalisation. Test is UKCA-marked.
Business Model
Aiming to extend UK sales, pursue US launch via CLIA lab partners, and use our patent platform and antigen partnerships to deepen Long Covid options and extend into Lyme, Hashimoto’s and autoimmunity.
Team
Andrew Shaw
CEO and Founder (Board Member)
Shivali Kohli
Director of Products
Philip James-Pemberton
Director of Research
Andrew Vincent
Chief Marketing Officer (Part Time)
Access to Investment Deck
UK & EU Investors
US, Canada, Japan, China & Others
For jurisdictions unable to invest through Crowdcube, you may contact Attomarker on info@attomarker.com or register at: